Optiscan Imaging (ASX:OIL) said 84 cases were imaged in its digital pathology study with Australian Clinical Labs (ASX:ACL), using its InForm digital pathology imaging device, according to a Thursday Australian bourse filing.
The device is providing real-time, slide-free cellular imaging at the point of contact. The cases imaged to date span a broad range of human tissue samples across multiple organs and systems as well as pathologies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.